CompletedEUCTR 2006-006540-54
Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multice...
This historical record does not confirm current site availability.
Historical research recordFrance + United KingdomDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- France · United Kingdom
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 300
- Sponsor
- Institut de Recherches Internationales Servier
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-006540-54
- Official title
Show the full official title
Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multice...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedFrance · United Kingdom
Registry details
Historical country statuses
- France — Completed
- United Kingdom — Completed
Questions about this study
Who is behind this study?
The study sponsor is Institut de Recherches Internationales Servier, a research institute.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
